AIC100 CAR T Cells

Phase 1Cell therapy

AAffyImmune Therapeutics, Inc.

AIC100 CAR T Cells is one of 42 biologic programs targeting Thyroid Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Thyroid CancerActive, not recruiting

Thyroid CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

210 competitors in Thyroid Cancer

#DrugCompanyPhaseTrials

Nexavar

Bayer

Phase 3

12 2

Koselugo

AstraZeneca

Phase 3

3 3

Glucophage

EMD Serono

Phase 3

2 4

Sutent

Pfizer

Phase 2

3 5

Iclusig

Takeda

Phase 2

2 6

Iressa

AstraZeneca

Phase 2

1 7

Mektovi

Pfizer

Phase 2

1 8

Stivarga

Bayer

Phase 2

1 9

Istodax

Teva

Phase 2

1 10

Actos

Takeda

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2030

Phase 1Active, not recruiting

Thyroid Cancer

NCT04420754

Clinical

Trials by Indication[1]

Thyroid Cancer1 trial

Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer

Active, not recruiting·AAffyImmune Therapeutics, Inc.·Phase 1·NCT04420754·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AIC100 CAR T Cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AIC100 CAR T Cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AIC100 CAR T Cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AffyImmune Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: AAffyImmune Therapeutics, Inc.

AIC100 CAR T Cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2030

Trials by Indication[1]

Thyroid Cancer1 trial

References

Drug Info

Quick Facts

Related News